SGLT2 inhibitors in heart failure management: Dissecting the path from diabetes to heart failure

SGLT2 inhibitors in heart failure management: Dissecting the path from diabetes to heart failure

CardiologyEndocrinologyInternal MedicineFamily MedicineGeneral Practice
A badge with ribbon in color black Cat 3B: 1 Point | An analog clock in color black 30 minutes | A black calendar with white triangle in center that has a black exclamation point in the middle 01 Jul 2022 

Overview

About this course

Across major cardiovascular outcome trials, sodium-glucose co-transporter 2 (SGLT2) inhibitors have consistently reduced the risk of heart failure (HF) in patients with diabetes and established cardiovascular disease. This e-learning module provides an overview of the latest real-world evidence of SGLT2 inhibitors for the prevention of HF and cardiorenal outcomes.


Learning outcomes

Upon completion of the educational activity, participants should be able to:
  • Understand the burden of HF and the associated guidelines for its prevention
  • Apply real-world evidence of SGLT2 inhibitors for the prevention of HF and cardiorenal outcomes
  • Utilize the latest robust clinical evidence on the use of SGLT2 inhibitors for treating patients with HF, irrespective of diabetes status.

Topics covered

  • Global prevalence of HF and classification
  • Guidance on use of biomarkers to screen for patients at risk of HF
  • Key findings and implications for clinical practice of the EMPA-REG OUTCOME, DAPA-HF and EMPEROR-Reduced studies
  • Role of SGLT2 inhibitors as renal protectants based on the CREDENCE study

1 CME Point Available

A certificate can be downloaded upon successful completion of the quiz. Please use the information on the certificate to claim your CME points.